Pancreatic and Hepatic Oncology Research

This study introduces SpheroMap Cytometry to analyze spatial CAF subsets in PDAC spheroids, revealing hypoxia's role in myCAF differentiation and stromal architecture.

This study identifies 16 novel cancer and T-cell markers in PDAC using scRNA-seq, highlighting T-cell exhaustion and potential therapeutic targets.

This study identifies HNF1A as an oncogenic driver of PDAC metastasis through upregulation of FGFR4 and shows that FGFR4 inhibition reduces metastasis in vitro and in vivo.

This study evaluates the concordance of claudin-18.2 expression between biopsy, resection, and recurrent pancreatic ductal adenocarcinoma specimens, finding high agreement and supporting its use as a biomarker for zolbetuximab therapy.

This study identifies NTN1/NEO1 as a key driver of pancreatic tumorigenesis and metastasis by promoting cancer stemness, EMT, and nerve innervation.

This study investigates the differential roles of HNF4α isoforms P1 and P2 in PDAC growth and differentiation, finding P2 supports growth better than P1.

This study shows that PP2A activation inhibits macropinocytosis and induces cell death in pancreatic ductal adenocarcinoma, suggesting PP2A activators could be used with metabolic inhibitors as a new therapeutic strategy.

This study develops a novel pancreatic cancer mouse model by expressing Myc and mutant Kras in adult acinar cells, showing metastasis and therapeutic resistance similar to human PDAc.

ODFormer predicts personalized drug responses in pancreatic cancer by simulating patient-derived organoids using transcriptomic and mutational data, outperforming existing methods and improving clinical outcomes.

The paper develops a 16-gene signature (MG-GEM) that predicts survival benefit from adjuvant gemcitabine in resectable pancreatic cancer based on glycation stress, outperforming existing signatures.

This study identifies HOXB6 and HOXB8 as regulators of immune-cancer cell interactions in pancreatic cancer, showing their role in promoting tumorigenesis and treatment resistance.

This study uses single-cell transcriptomics to show that hypoxia in organoid models influences transcriptional subtypes in pancreatic cancer.

This study identifies cellular and microenvironmental factors contributing to radiation therapy resistance in pancreatic cancer using spatial transcriptomics and single-cell RNA sequencing.

This study shows that loss of HNF1B contributes to IPMN initiation and identifies its role as a tumor suppressor in pancreatic ductal cells.

The paper introduces FunCN, a method to analyze cellular neighborhoods in PDAC, revealing distinct immune interactions in primary and metastatic sites.

The paper identifies β-catenin, LEF-1, MMP7, and SFRP5 as biomarkers associated with prognosis in pancreatic cancer using RNA sequencing, qPCR, and immunohistochemistry.

This study identifies Serpinb2 and Serpine1 as key factors in pancreatic cancer that remodel the tumor microenvironment to promote immune evasion and tumor progression.

This study shows that pancreas-specific BCKDK inhibition accelerates pancreatic cancer while systemic BCKDK inhibition reduces tumor formation.

ONG41008 eradicates pancreatic ductal adenocarcinoma and lung cancer in mice by inducing senescence-coupled apoptosis and inhibiting tumor blood vessels.

The paper uses spatial imaging and organoid models to identify therapy-resistant CD44v9+ cancer stem cells in PDAC and show that cabozantinib may enhance immunotherapy by altering the tumor microenvironment.

The paper identifies Dclk1-expressing cells in the pancreas and reveals their role in inhibiting pancreatic tumor progression through a tuft cell-ILC2 axis.

This study shows that aging stromal cells in pancreatic cancer promote immune exclusion and metastasis, and that rejuvenating these cells can reverse these effects.

This study investigates KCNN4 gene expression in pancreatic adenocarcinoma using bioinformatics, finding its expression correlates with survival and identifies associated biological functions.

This study uses patient-derived organoids to predict drug response and track tumor evolution in pancreatic cancer.

This study identifies statins as effective in targeting chemoresistant pancreatic cancer by inhibiting cholesterol metabolism and protein glycosylation, showing clinical benefit in a phase 2 trial.

This study shows that oncogenic KRAS cells in the adult pancreas evade elimination by using Wnt signaling and cell dormancy.

This study identifies FGFR2 as a key driver in early pancreatic tumorigenesis, showing that its inhibition can delay tumor formation and extend survival in mouse models.

ADT-1004, a pan-RAS inhibitor, shows strong antitumor activity in pancreatic ductal adenocarcinoma models with high selectivity and tolerable dosing.

This study identifies a DNA methylation signature preserved during pancreatic carcinogenesis that distinguishes PDAC origins and influences tumor behavior.